Phospholipid curcumin Meriva Promising in Treatment of Nonalcoholic Steatohepatitis and Kidney Disease: Study Dr Riya Dave9 July 2024 7:45 AM ISTResearchers recently have found that Meriva, a phospholipid formulation of curcumin, is both safe and effective in improving liver histology, kidney...
Ionis announces positive results from Phase 2 study of ION224 to treat NASH/MASH Kajal Rajput17 March 2024 5:00 PM ISTNew Delhi: Ionis Pharmaceuticals announced positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor in...
Standard of Care in Diabetes 2024: ADA update emphasises screening people with diabetes for NAFLD and NASH Medha Baranwal25 Dec 2023 9:00 AM ISTUSA: The American Diabetes Association (ADA) has released Standards of Care in Diabetes-2024 which includes the ADA's current clinical practice...
Study unravels mechanism behind omega-3 fatty acid-induced improvement in NASH and liver health Medha Baranwal21 Nov 2023 9:45 AM ISTUSA: A recent study published in EMBO Molecular Medicine has revealed a novel mechanism through which omega-3 polyunsaturated fatty acids (PUFA)...
Pegozafermin, a potential treatment for improving fibrosis in NASH patients: Phase 2b Trial Dr. Kamal Kant Kohli5 July 2023 8:00 PM ISTUSA: The positive outcomes of a phase 2b trial support the further advancement of pegozafermin into phase 3 trials for NASH treatment. If successful,...
Investigational FGF21 analogue improves fibrosis in NASH patients: Phase 2b trial Medha Baranwal27 Jun 2023 11:00 AM ISTUSA: Treatment with an investigational FGF21 analogue, pegozafermin, improved fibrosis in patients with NASH (nonalcoholic steatohepatitis), according...
Novo Nordisk, Ventus Therapeutics collaborate for NLRP3 Inhibitor Program Ruchika Sharma5 Oct 2022 11:00 AM ISTVentus retains the right to develop NLRP3 inhibitors for certain systemic diseases, including specific inflammatory and respiratory diseases.
Visceral Fat Volume correlates with Hepatic Fibrosis in NAFLD Patients Isra Zaman8 Sept 2022 10:00 AM ISTStudy in JAPI aimed to calculate visceral fat volume at the L3-L4 vertebral level and its association with hepatic fibrosis assessed by transient...
Intercept to go back to USFDA with its NASH treatment application Ruchika Sharma10 July 2022 9:30 AM ISTNew Jersey: Intercept Pharmaceuticals Inc will resubmit its application for approval of its therapy for a chronic liver disease to the U.S. Food and...
Resmetirom reduces liver fat and improves quality of life of NASH patients Jacinthlyn Sylvia15 Jun 2022 8:00 PM ISTUSA: A new article published in Clinical Gastroenterology and Hepatology shows that in nonalcoholic steatohepatitis (NASH) patients taking resmetirom,...
Anti-diabetic drug and NASH: Current Options in 2022 Dr. Kamal Kant Kohli9 Jun 2022 11:06 AM ISTIntroduction and Background Nonalcoholic steatohepatitis (NASH) is a more aggressive form of nonalcoholic fatty liver disease, which can increase the...
ADA releases standard of medical care in 2022, here are the important details Dr. Nandita Mohan23 Dec 2021 5:51 PM ISTBased upon the latest scientific diabetes research and clinical trials, the Standards of Care is the gold-standard for professionals in the medical...
